Initial Testing of the MDM2 Inhibitor RG7112 by the Pediatric Preclinical Testing Program

BACKGROUND: RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively lo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Carol, Hernan, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Billups, Catherine A., Geier, Brian, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3495996/
https://ncbi.nlm.nih.gov/pubmed/22753001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24235
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados